United Kingdom (UK)
Recombinant monoclonal antibody to EPCAM. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma B38.1.
UniProt Accession Number of Target Protein: P16422
Alternative Name(s) of Target: DIAR5; epithelial cell adhesion molecule; ESA; KSA; M4S1; MK-1; EGP-2; ING-1
Immunogen: Mice were immunized with membrane-enriched fractions of human metastic mammary carcinoma cells. The spleens were extracted and fused with NS-1 to generate primary hybridoma cultures. These were screened using solid phase RIA for those which were reactive with metastic mammary tumor cells from livers but were not reactive with healthy livers.
Specificity: Reactive against 80% of primary mammary tumors. Has a binding constant in the nM range.
Application Notes: Has been used to generate a human engineered monoclonal antibody (Ammons et al, 2003). B38.1 has been shown to be able to mediate antibody-dependent cytotoxicity (Robinson et al, 1991). It has undergone clinical trials as an anti-carcinoma drug (de Bono et al, 2002 and Better et al, 2002). It has also been used in ELISAs to test the reactivity of its humanised construct, ING-1, that it has an affinity in the nM range by competition assays, and it has been shown to be active in vivo (Ammons et al, 2003).
Antibody first published in:
Colcher et al Monoclonal antibodies reactive with human breast cancer Proc Natl Acad Sci U S A. 1981 May;78(5):3199-203 PMID:6789331
Note on publication:
Describes the formation of this antibody and others against metastic mammary carcinoma cells. Describes the characterisation of these antibodies including identifying a number of carcinoma types, other than mammary, that they are reactive against.